ES8401321A1 - Procedimiento para la obtencion de derivados de piridina. - Google Patents

Procedimiento para la obtencion de derivados de piridina.

Info

Publication number
ES8401321A1
ES8401321A1 ES520526A ES520526A ES8401321A1 ES 8401321 A1 ES8401321 A1 ES 8401321A1 ES 520526 A ES520526 A ES 520526A ES 520526 A ES520526 A ES 520526A ES 8401321 A1 ES8401321 A1 ES 8401321A1
Authority
ES
Spain
Prior art keywords
antihypoxemia
ischemia
medicaments
manufacture
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES520526A
Other languages
English (en)
Other versions
ES520526A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of ES520526A0 publication Critical patent/ES520526A0/es
Publication of ES8401321A1 publication Critical patent/ES8401321A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE DERIVADOS DE PIRIDINA DE FORMULA (I) EN LA QUE X, Y, R, R Y R PUEDEN SER VARIOS TIPOS DE RADICALES. CONSISTE EN LA REACCION DE OXIDACION DE DERIVADOS DE 1,4-DIHIDROPIRIDINA, DE FORMULA (II), EN LA QUE TODOS LOS SIMBOLOS TIENEN EL MISMO SIGNIFICADO QUE EN LA FORMULA (I). LA OXIDACION SE LLEVA A CABO CON UNO DE DIVERSOS AGENTES OXIDANTES, O MEDIANTE OXIDACION ANODICA, EN UN DISOLVENTE INERTE, A UNA TEMPERATURA COMPRENDIDA ENTRE 0º Y 200º. ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DE TRANSTORNOS EN EL SISTEMANERVIOSO CENTRAL.
ES520526A 1982-03-13 1983-03-11 Procedimiento para la obtencion de derivados de piridina. Expired ES8401321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823209276 DE3209276A1 (de) 1982-03-13 1982-03-13 Arzneimittel mit antihypoxischer und ischaemie-protektiver wirkung

Publications (2)

Publication Number Publication Date
ES520526A0 ES520526A0 (es) 1983-12-16
ES8401321A1 true ES8401321A1 (es) 1983-12-16

Family

ID=6158230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES520526A Expired ES8401321A1 (es) 1982-03-13 1983-03-11 Procedimiento para la obtencion de derivados de piridina.

Country Status (6)

Country Link
US (1) US4497821A (es)
EP (1) EP0088938B1 (es)
JP (1) JPS58167570A (es)
AT (1) ATE19514T1 (es)
DE (2) DE3209276A1 (es)
ES (1) ES8401321A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209274A1 (de) * 1982-03-13 1983-09-15 Bayer Ag, 5090 Leverkusen Pyridincarbonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS58185821U (ja) * 1982-06-02 1983-12-10 日産自動車株式会社 ウインドシ−ルド
DE3410645A1 (de) * 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3424342A1 (de) * 1984-07-03 1986-01-09 Bayer Ag, 5090 Leverkusen 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3,5-dicarbonsaeure-isopropyl-(2-(3-trifluormethylphenoxy)-ethyl)-ester, mehrere verfahren zu seiner herstellung sowie seine verwendung in arzneimitteln
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
US4659717A (en) * 1985-08-21 1987-04-21 Eli Lilly And Company Dihydropyridines useful in the treatment of angina and stroke
GB8530602D0 (en) * 1985-12-12 1986-01-22 Fujisawa Pharmaceutical Co Heterocyclic compounds
US4990507A (en) * 1985-12-12 1991-02-05 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds, and composition comprising the same
CA1312611C (en) * 1987-07-01 1993-01-12 Yamanouchi Pharmaceutical Co., Ltd. Pyridine derivatives, process for production thereof and pharmaceutical composition containing them
GB8905526D0 (en) * 1989-03-10 1989-04-19 Fujisawa Pharmaceutical Co N-containing heterocyclic compounds,processes for the preparation thereof and composition comprising the same
DE59410255D1 (de) 1993-12-10 2003-04-17 Bayer Ag Phenyl-substituierte 1,4-Dihydropyridine mit cerebraler Aktivität
DE4430639A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
CH692199A8 (fr) * 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
EP1663227A2 (en) * 2003-09-10 2006-06-07 Synta Pharmaceuticals Corporation Dihydropyridine compounds for treating or preventing metabolic disorders
RU2245329C1 (ru) * 2003-09-10 2005-01-27 ГУП "Всероссийский научный центр по безопасности биологически активных веществ" (ГУП "ВНЦ БАВ") Гамма-гидроксипропиламиний-5-гидроксиникотинат, обладающий противоишемической, антиаритмической и гиполипидемической активностью
WO2022114187A1 (ja) * 2020-11-30 2022-06-02 国立大学法人九州大学 ミトコンドリア過剰分裂阻害作用を有する化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1440647A (fr) * 1963-12-10 1966-06-03 Ciba Geigy Nouveaux agents pesticides
US3907808A (en) * 1971-05-17 1975-09-23 Sterling Drug Inc 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives
US3922278A (en) * 1972-06-12 1975-11-25 Sterling Drug Inc 4-(3-Nitrophenyl)-3,5-pyridinedicarboxylic acid
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
DE3023820A1 (de) * 1980-06-25 1982-01-14 Bayer Ag, 5090 Leverkusen 4,4-disubstituierte spiro-1,4-dihydropyridine, ein verfahren zu ihrer herstellung, sowie ihre verwendung als zwischenprodukt

Also Published As

Publication number Publication date
JPS58167570A (ja) 1983-10-03
EP0088938A1 (de) 1983-09-21
DE3363248D1 (en) 1986-06-05
ES520526A0 (es) 1983-12-16
US4497821A (en) 1985-02-05
EP0088938B1 (de) 1986-04-30
DE3209276A1 (de) 1983-09-15
ATE19514T1 (de) 1986-05-15

Similar Documents

Publication Publication Date Title
ES8401321A1 (es) Procedimiento para la obtencion de derivados de piridina.
ZA831633B (en) New compounds,processes for their preparation and their use as medicaments
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
ATE12224T1 (de) Verbindungen mit antifibrinolytischer wirksamkeit.
JPS552693A (en) 1*22dihydrooquinolinee22one derivative*its manufacture and allurgic affection therapeutic drug containing it
JPS57116089A (en) Novel cephalosporin derivatives, manufacture and drug
GB9215844D0 (en) Novel compounds
ZA831691B (en) Pyridinecarboxylic esters,processes for their preparation and their use as medicaments
ES8400440A1 (es) "procedimiento para preparar nuevas triazoloquinazolonas".
ATE58902T1 (de) Penem-derivate.
ES479388A1 (es) Procedimiento para la obtencion de derivados de cromanona.
ES8604121A1 (es) Procedimiento para la preparacion de esteres de acido guani-dinobenzoico
ES8405020A1 (es) Un procedimiento para la preparacion de derivados de fosfolipidos.
AU6679786A (en) 5-aminoalkyl-beta-carboline derivatives, their production and their use as drugs
ES8103746A1 (es) Procedimiento para la preparacion de 4-aril-5,6,7,8-tetrahi-dropirazolo (3,4b) (1,5) diazepin-1h,4h-5,7-dionas
ES8305302A1 (es) Procedimiento para la obtencion de fenil-ciclopropancarboxilatos sustituidos.
YU216483A (en) Process for preparing new semicarbazides
ES8400849A1 (es) Procedimiento para la obtencion de oximinoacetanilidas sustituidas.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19960603